AU2003226401A8 - Gelsolin as a prognostic marker of artherosclerotic diseases - Google Patents

Gelsolin as a prognostic marker of artherosclerotic diseases

Info

Publication number
AU2003226401A8
AU2003226401A8 AU2003226401A AU2003226401A AU2003226401A8 AU 2003226401 A8 AU2003226401 A8 AU 2003226401A8 AU 2003226401 A AU2003226401 A AU 2003226401A AU 2003226401 A AU2003226401 A AU 2003226401A AU 2003226401 A8 AU2003226401 A8 AU 2003226401A8
Authority
AU
Australia
Prior art keywords
gelsolin
prognostic marker
artherosclerotic
diseases
artherosclerotic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003226401A
Other versions
AU2003226401A1 (en
Inventor
Thomas P Stossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2003226401A1 publication Critical patent/AU2003226401A1/en
Publication of AU2003226401A8 publication Critical patent/AU2003226401A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
AU2003226401A 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases Abandoned AU2003226401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37304302P 2002-04-16 2002-04-16
US60/373,043 2002-04-16
PCT/US2003/011722 WO2003088811A2 (en) 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases

Publications (2)

Publication Number Publication Date
AU2003226401A1 AU2003226401A1 (en) 2003-11-03
AU2003226401A8 true AU2003226401A8 (en) 2003-11-03

Family

ID=29250950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003226401A Abandoned AU2003226401A1 (en) 2002-04-16 2003-04-16 Gelsolin as a prognostic marker of artherosclerotic diseases

Country Status (2)

Country Link
AU (1) AU2003226401A1 (en)
WO (1) WO2003088811A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1755661T3 (en) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolin for use in treating infections
CA2567223A1 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
WO2007106577A2 (en) 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
PT3279663T (en) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Use of gelsolin to diagnose and treat inflammatory diseases
ES2634263T3 (en) 2008-01-25 2017-09-27 The General Hospital Corporation Therapeutic diagnostic uses of gelsolin in renal failure
RU2563987C2 (en) * 2010-10-20 2015-09-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Biomarker for alzheimer's disease or mild cognitive impairment
EP2725360A1 (en) * 2012-10-24 2014-04-30 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Biomarkers for the prognosis of ischemic stroke
CN103242304A (en) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 Synthetic method of anti-inflammatory drug tenidap sodium
CN107300589A (en) * 2017-04-18 2017-10-27 广州仁恒医药科技股份有限公司 A kind of chromatographic purity assay method of Difluprednate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663050B2 (en) * 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds

Also Published As

Publication number Publication date
AU2003226401A1 (en) 2003-11-03
WO2003088811A3 (en) 2004-02-26
WO2003088811A2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
HK1048854B (en) Improved timepiece
HK1090435A1 (en) World timepiece
AU2003210829A8 (en) Battery-powered wristwatch
PT1470732T (en) Provision of location information
HK1062202A1 (en) Watchcase
GB2394323B (en) High-throughput uart interfaces
AU2003226401A8 (en) Gelsolin as a prognostic marker of artherosclerotic diseases
GB0200738D0 (en) Improvements relating to illuminated jewellery
GB0210368D0 (en) Marker pens
HK1083518A1 (en) Coloured labels
AU2003270113A8 (en) Isolated mapping point
GB0210159D0 (en) Improvements relating to signal enhancement
AU2003233286A1 (en) Pth derivatives resistant to skin proteases
IL148158A0 (en) Marker for sign
IL163578A0 (en) Use of the mal protein as a tumour marker
EP1573055A4 (en) Genetic diagnosis of depression
GB2386189B (en) Movement gauge
GB0228694D0 (en) Novel threapeutic target
AU2003211311A1 (en) A fat mesuring scale
AU2003226975A1 (en) Analysis of a protein expression pattern
GB0312052D0 (en) Marker bouy
AU2002241209A1 (en) Provision of location information
GB0221063D0 (en) Improvements relating to information processing
GB0200244D0 (en) Improvements relating to information recordal
GB0214272D0 (en) Improvements relating to information recordal

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase